© 1996 American Heart Association, Inc.
Articles |
Heparin-Induced Overexpression of Basic Fibroblast Growth Factor, Basic Fibroblast Growth Factor Receptor, and Cell-Associated Proteoheparan Sulfate in Cultured Coronary Smooth Muscle Cells
the Institute for Arteriosclerosis Research, Division of Molecular Cardiology (A.S.-R., A.S., G.B.) and the Institute for Physiological Chemistry and Pathobiochemistry (E.B.), University of Münster, and the Department of Cardiology and Angiology (G.B.), Hospital of the University of Münster, Germany.
Correspondence to Prof Dr E. Buddecke, Institut für Physiologische Chemie und Pathobiochemie, Waldeyerstraße 15, D-48149 Münster, Germany.
Abstract
Basic fibroblast growth factor (bFGF), a potent mitogen for arterial smooth muscle cells (SMCs), plays a pivotal role in the pathogenesis of arteriosclerosis and restenosis. Heparin in nanogram quantities may promote or even be required for binding of bFGF to its cognate receptor. Conversely, heparin in microgram doses is a strong inhibitor of arterial SMC replication in vitro and in vivo. Bovine coronary SMCs (cSMCs) express bFGF, bFGF receptor (FGF-R1), and cell membrane–integrated proteoheparan sulfate (HSPG). These three molecules are known to form a trimolecular complex that promotes signal transduction and mitogenesis. The bFGF synthesized by cSMCs is distributed to an intracellular and a pericellular compartment. Resting cultured cells retain about 80% of their bFGF intracellularly; 20% is found in the pericellular region. During proliferation, 70% to 80% of total bFGF is expressed in the pericellular compartment. Trypsinization generates soluble forms of the complex of bFGF with the ectodomains of the bFGF receptor and cell membrane–integrated HSPG in the pericellular compartment, thus allowing quantification of pericellular bFGF by a highly specific enzyme immunoassay. Standard heparin inhibits the proliferation of cSMCs by up to 80% in a concentration range between 10 and 100 µg/mL medium in a dose-dependent manner but increases the protein content of cSMCs compared with proliferating control cells. The heparin-induced increase in cellular protein content includes a 60% to 100% increase in the expression of pericellular bFGF, FGF-R1, and cell membrane–integrated HSPG. Thus, under heparin treatment, the heparan sulfate side chains of cell membrane–integrated HSPG incorporate more [35S]sulfate, and the proportion of [35S]heparan sulfate among total glycosaminoglycans increases from 36% to 52%. Fluorescence-activated cell sorting analysis and [3H]thymidine incorporation experiments provide evidence for multiple effects of heparin, including blocks at early and late checkpoints of the cell cycle in heparin-treated cells. These results indicate that heparin, despite its antiproliferative potency, stimulates the expression of all components of the bFGF system even in coronary SMCs in which growth is inhibited.
Key Words: heparin • bFGF • bFGF receptor • heparan sulfate • coronary smooth muscle cells
This article has been cited by other articles:
 |
|
 |
|
  A. Skaletz-Rorowski, H. Eschert, J. Leng, B. Stallmeyer, J. R. Sindermann, E. Pulawski, and G. Breithardt PKC {delta}-induced activation of MAPK pathway is required for bFGF-stimulated proliferation of coronary smooth muscle cells Cardiovasc Res, July 1, 2005; 67(1): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. O'Blenes, S. L. Merklinger, A. Jegatheeswaran, A. Campbell, M. Rabinovitch, I. Rebeyka, and G. Van Arsdell Low Molecular Weight Heparin and Unfractionated Heparin Are Both Effective at Accelerating Pulmonary Vascular Maturation in Neonatal Rabbits Circulation, September 9, 2003; 108(90101): II-161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kiesz, P. Buszman, J. L. Martin, E. Deutsch, M. M. Rozek, E. Gaszewska, M. Rewicki, P. Seweryniak, M. Kosmider, and M. Tendera Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial : Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) Circulation, January 2, 2001; 103(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Skaletz-Rorowski, H. Eschert, E. Pawlus, and G. Breithardt Molecular effects of HMG-CoA reductase inhibitors on smooth muscle cell proliferation J. Am. Coll. Cardiol., January 1, 2001; 37(1): 337 - 338. [Full Text] [PDF]
|
|
|
|
|
|
M. F. Flanagan, T. Aoyagi, L. W. Arnold, C. Maute, A. M. Fujii, J. Currier, D. Bergau, H. B. Warren, and K. Rakusan Effects of Chronic Heparin Administration on Coronary Vascular Adaptation to Hypertension and Ventricular Hypertrophy in Sheep Circulation, August 31, 1999; 100(9): 981 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Skaletz-Rorowski, J. Waltenberger, J. G. Muller, E. Pawlus, K. Pinkernell, and G. Breithardt Protein Kinase C Mediates Basic Fibroblast Growth Factor–Induced Proliferation Through Mitogen-Activated Protein Kinase in Coronary Smooth Muscle Cells Arterioscler Thromb Vasc Biol, July 1, 1999; 19(7): 1608 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Richardson, V. Trinkaus-Randall, and M. A. Nugent Regulation of Basic Fibroblast Growth Factor Binding and Activity by Cell Density and Heparan Sulfate J. Biol. Chem., May 7, 1999; 274(19): 13534 - 13540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Sindermann and K. L. March Heparin Responsiveness In Vitro as a Prognostic Tool for Vascular Graft Stenosis : A Tale of Two Cell Types? Circulation, June 30, 1998; 97(25): 2486 - 2490. [Full Text] [PDF]
|
|